

MECHANISMS OF VASCULAR DISEASE:

A REFERENCE BOOK FOR VASCULAR SPECIALISTS



EDITED BY ROBERT FITRIDGE AND MATTHEW THOMPSON
COMPLETELY UPDATED EDITION 2011

Mechanisms of Vascular Disease

Mechanisms of Vascular Disease: A Reference Book for Vascular Specialists

Robert Fitridge

The University of Adelaide, The Queen Elizabeth Hospital, Woodville, Australia

Matthew Thompson

St George's Hospital Medical School, London, UK



BARR SMITH PRESS

An imprint of
The University of Adelaide Press

Published in Adelaide by

The University of Adelaide, Barr Smith Press
Barr Smith Library
The University of Adelaide
South Australia 5005
press@adelaide.edu.au
www.adelaide.edu.au/press

The University of Adelaide Press publishes peer-reviewed scholarly works by staff via Open Access online editions and print editions.

The Barr Smith Press is an imprint of the University of Adelaide Press, reserved for scholarly works which are not available in Open Access, as well as titles of interest to the University and its associates. The Barr Smith Press logo features a woodcut of the original Barr Smith Library entrance.

© The Contributors 2011

This book is copyright. Apart from any fair dealing for the purposes of private study, research, criticism or review as permitted under the Copyright Act, no part may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise without the prior written permission. Address all inquiries to the Director at the above address.

This CIP cataloguing for this work is as follows;

Mechanisms of vascular disease : a reference book for vascular surgeons / Robert Fitridge, Matthew Thompson, [editors].

1. Blood vessels, Diseases.
2. Blood vessels, Surgery.

- I. Fitridge, Robert
- II. Thompson, M. M.

For the full Cataloguing-in-Publication data please contact National Library of Australia:
cip@nla.gov.au

ISBN (paperback) 978-0-9871718-2-5

Book design: Midland Typesetters

Cover design: Emma Spoehr, based on a diagram by Dave Heinrich of the Medical Illustration and Media Unit, Flinders Medical Centre

Paperback edition printed by Griffin Press, South Australia

Table of Contents

Contributors	vii
Detailed Contents	xi
1. Endothelium	1 <i>Paul Kerr, Raymond Tam, Frances Plane (Calgary, Canada)</i>
2. Vascular smooth muscle structure and function	13 <i>David Wilson (Adelaide, Australia)</i>
3. Atherosclerosis	25 <i>Gillian Cockerill, Qingbo Xu (London, UK)</i>
4. Mechanisms of plaque rupture	43 <i>Ian Loftus (London, UK)</i>
5. Current and emerging therapies in atheroprotection	79 <i>Stephen Nicholls, Rishi Puri (Cleveland, USA)</i>
6. Molecular approaches to revascularisation in peripheral vascular disease	103 <i>Greg McMahon, Mark McCarthy (Leicester, UK)</i>
7. Biology of restenosis and targets for intervention	115 <i>Richard Kenagy (Seattle, USA)</i>
8. Vascular arterial haemodynamics	153 <i>Michael Lawrence-Brown, Kurt Liffman, James Semmens, Ilija Sutalo (Melbourne & Perth, Australia)</i>
9. Physiological haemostasis	177 <i>Simon McRae (Adelaide, Australia)</i>
10. Hypercoagulable states	189 <i>Simon McRae (Adelaide, Australia)</i>
11. Platelets in the pathogenesis of vascular disease and their role as a therapeutic target	201 <i>Sandeep Prabhu, Rahul Sharma, Karlheinz Peter (Melbourne, Australia)</i>
12. Pathogenesis of aortic aneurysms	227 <i>Jonathan Golledge, Guo-Ping Shi, Paul Norman (Townsville & Perth, Australia; Boston, USA)</i>
13. Pharmacological treatment of aneurysms	247 <i>Matthew Thompson, Janet Powell (London, UK)</i>
14. Aortic dissection and connective tissue disorders	255 <i>Mark Hamilton (Adelaide, Australia)</i>
15. Biomarkers in vascular disease	277 <i>Ian Nordon, Robert Hinchliffe (London, UK)</i>
16. Pathophysiology and principles of management of vasculitis and Raynaud's phenomenon	295 <i>Martin Veller (Johannesburg, South Africa)</i>
17. SIRS, sepsis and multiorgan failure	315 <i>Vishwanath Biradar, John Moran (Adelaide, Australia)</i>
18. Pathophysiology of reperfusion injury	331 <i>Prue Cowled, Robert Fitridge (Adelaide, Australia)</i>
19. Compartment syndrome	351 <i>Edward Choke, Robert Sayers, Matthew Bown (Leicester, UK)</i>
20. Pathophysiology of pain	375 <i>Stephan Schug, Helen Daly, Kathryn Stannard (Perth, Australia)</i>

21. Postamputation pain 389
Stephan Schug, Gail Gillespie (Perth, Australia)
 22. Treatment of neuropathic pain 401
Stephan Schug, Kathryn Stannard (Perth, Australia)
 23. Principles of wound healing 423
Gregory Schultz, Gloria Chin, Lyle Moldawer, Robert Diegelmann (Florida, USA)
 24. Pathophysiology and principles of varicose veins 451
Andrew Bradbury (Birmingham, UK)
 25. Chronic venous insufficiency and leg ulceration: Principles and vascular biology 459
Michael Stacey (Perth, Australia)
 26. Pathophysiology and principles of management of the diabetic foot 475
David Armstrong, Timothy Fisher, Brian Lepow, Matthew White, Joseph Mills (Tucson, USA)
 27. Lymphoedema – Principles, genetics and pathophysiology 497
Matt Waltham (London, UK)
 28. Graft materials past and future 511
Mital Desai, George Hamilton (London, UK)
 29. Pathophysiology of vascular graft infections 537
Mauro Vicaretti (Sydney, Australia)
- Index 549

List of Contributors

David G Armstrong
The University of Arizona
Southern Arizona Limb Salvage Alliance
Tucson, AZ
USA

Vishwanath Biradar
Intensive Care Unit
The Queen Elizabeth Hospital
Woodville, SA
Australia

Matthew Bown
Department of Vascular Surgery
University of Leicester
Leicester
UK

Andrew W Bradbury
University Department of Vascular Surgery
Birmingham Heartlands Hospital
Birmingham
UK

Edward Choke
Department of Vascular Surgery
University of Leicester
Leicester
UK

Gillian Cockerill
Department of Clinical Sciences
St George's Hospital Medical School
London
UK

Prue Cowled
Department of Surgery
University of Adelaide
The Queen Elizabeth Hospital
Woodville, SA
Australia

Helen Daly
Royal Perth Hospital
Perth, WA
Australia

Mital Desai
University Department of Vascular Surgery
Royal Free Hospital
University College
London
UK

Robert F Diegelmann
Department of Biochemistry
Medical College of Virginia
Richmond, VA
USA

Timothy K Fisher
Rashid Centre for Diabetes and Research
Sheikh Khalifa Hospital
Ajmon
UAE

Robert A Fitridge
Department of Surgery
University of Adelaide
The Queen Elizabeth Hospital
Woodville, SA
Australia

Gail Gillespie
Royal Perth Hospital
Perth, WA
Australia

Jonathan Golledge
Vascular Biology Unit
School of Medicine & Dentistry
James Cook University
Townsville, QLD
Australia

George Hamilton
University Department of Vascular Surgery
Royal Free Hospital
University College
London
UK

Mark Hamilton
Department of Surgery
University of Adelaide
The Queen Elizabeth Hospital
Woodville, SA
Australia

Robert J Hinchliffe
St George's Vascular Institute
St George's Hospital
London
UK

Richard D Kenagy
Department of Surgery
University of Washington
Seattle, WA
USA

Paul Kerr
Department of Pharmacology
University of Alberta
Alberta
Canada

Michael MD Lawrence-Brown
Curtin Health Innovation Research
Institute
Curtin University
Perth, WA
Australia

Brian Lepow
The University of Arizona
Department of Surgery
Southern Arizona Limb Salvage Alliance
Tucson, AZ
USA

Kurt Liffman
CSIRO Material Science & Engineering
and School of Mathematical Sciences
Monash University
Melbourne, Vic
Australia

Ian Loftus
Department of Vascular Surgery
St George's Hospital
London
UK

Mark J McCarthy
Department of Surgery and Cardiovascular
Sciences
University of Leicester
Leicester
UK

Greg S McMahon
Department of Surgery and Cardiovascular
Sciences
University of Leicester
Leicester
UK

Simon McRae
Adult Haemophilia Treatment Centre
SA Pathology
Adelaide, SA
Australia

Joseph L Mills
The University of Arizona
Southern Arizona Limb Salvage Alliance
Tucson, AZ
USA

Lyle Moldawer
Department of Surgery
University of Florida
Gainesville, FL
USA

John L Moran
Faculty of Health Sciences
University of Adelaide
The Queen Elizabeth Hospital
Woodville, SA
Australia

Stephen Nicholls
The Heart and Vascular Institute
Cleveland Clinic
Cleveland, OH
USA

Ian M Nordon
St George's Vascular Institute
St George's Hospital
London
UK

Paul E Norman
School of Surgery
University of WA
Fremantle, WA
Australia

Karlheinz Peter
Baker IDI Heart & Diabetes Institute
Melbourne, Vic
Australia

Frances Plane
Department of Pharmacology
University of Alberta
Alberta
Canada

Janet T Powell
Imperial College
London
UK

Sandeep Prabhu
Baker IDI Heart & Diabetes Institute
Alfred Hospital
Melbourne, Vic
Australia

Rishi Puri
The Heart and Vascular Institute
Cleveland Clinic
Cleveland, OH
USA

Stephan A Schug
Royal Perth Hospital
Perth, WA
Australia

Gregory S Schultz
Department of Obstetrics and Gynaecology
University of Florida
Gainesville, FL
USA

Rahul Sharma
Baker IDI Heart & Diabetes Institute
Alfred Hospital
Melbourne, Vic
Australia

Guo-Ping Shi
Department of Cardiovascular Medicine
Brigham & Women's Hospital
Harvard Medical School
Boston, MA
USA

Michael Stacey
University Department of Surgery
Fremantle Hospital
Fremantle, WA
Australia

Ilija D Sutalo
CSIRO Material Science & Engineering
and Curtin Health Innovation
Research Institute
Curtin University
Highett, Vic

Raymond Tam
Department of Pharmacology
University of Alberta
Alberta
Canada

Matthew Thompson
St Georges Hospital Medical School
London
UK

Martin Veller
Department of Surgery
University of Witwatersrand
Johannesburg
South Africa

Mauro Vicaretti
Department of Vascular Surgery
Westmead Hospital
Westmead, NSW
Australia

Matt Waltham
Academic Department of Surgery
St Thomas' Hospital
London
UK

Matthew L White
Vascular and Endovascular Surgery
University of Arizona
Tucson, AZ
USA

David P Wilson
School of Medical Sciences
Discipline of Physiology
University of Adelaide
Adelaide SA
Australia

Qingbo Xu
Department of Cardiology
Kings College
University of London
UK

Detailed Contents

CHAPTER 1 – ENDOTHELIUM

Paul Kerr, Raymond Tam, Frances Plane

Introduction 1

Endothelium-dependent regulation of vascular tone 2

Angiogenesis 7

Haemostasis 8

Inflammation 9

Conclusions 10

References

CHAPTER 2 – VASCULAR SMOOTH MUSCLE STRUCTURE AND FUNCTION

David Wilson

Introduction 13

Smooth muscle (vascular) structure

Cytoskeleton 14

Contractile myofilament

Functional regulation of vascular smooth muscle: Neuronal, hormonal, receptor mediated 15

Smooth muscle function 17

Myofilament basis of smooth muscle contraction and relaxation

Smooth muscle contraction and relaxation 18

Ion channels important in the regulation of smooth muscle function

Regulation of cellular Ca^{2+}

Sources of cytosolic Ca^{2+} entry 19

Potassium channels

Endothelial regulation of smooth muscle vasodilatation 20

Smooth muscle proliferation and vascular remodeling 20

Summary 22

References

CHAPTER 3 – ATHEROSCLEROSIS

Gillian Cockerill, Qingbo Xu

Introduction 25

Atherosclerotic lesions 26

Fatty streaks

Plaque or atheroma

Hypercholesterolemia and oxidised-LDL 27

High-density lipoproteins role in atheroprotection 28

Hypertension and biomechanical stress 29

Biomechanical stress-induced cell death 30

Biomechanical stress and inflammation 31

Biomechanical stress-induced smooth muscle cell proliferation 32

Infections and heat shock proteins

Infections

Heat shock proteins 33

Infections and HSP expression

Infections, sHSP and innate immunity 34

Immune responses 36

MHC class II antigens and T cells

Oxidised LDL as a candidate antigen

HSP60 as a candidate antigen 37

B2-glycoprotein Ib as a candidate antigen

Inflammation

C-reactive protein	38
CD40/CD40L	
Summary and perspectives	39
References	

CHAPTER 4 – MECHANISMS OF PLAQUE RUPTURE

Ian Loftus

Introduction 43

Evidence for the ‘plaque rupture theory’ 44

Coronary circulation

Cerebral circulation

The role of individual components of the arterial wall

The endothelium 45

The lipid core 47

The cap of the plaque 49

Smooth muscle cells and collagen production 50

Macrophages and collagen degradation 51

The vessel lumen 56

The role of angiogenesis in plaque rupture

The role of infectious agents in plaque rupture 57

Risk prediction of plaque instability 58

Imaging

Blood markers 59

Therapy aimed at plaque stabilisation

HMG Co-A reductase inhibitors 60

MMP inhibition

Tissue inhibitors of metalloproteinases (TIMPs) 61

Synthetic MMP inhibitors

Doxycycline

ACE inhibitors

Summary 62

References 63

CHAPTER 5 – CURRENT AND EMERGING THERAPIES IN ATHEROPROTECTION

Stephen Nicholls, Rishi Puri

Background 79

Pathology

Risk factor modification 80

Statins, LDL lowering and C-reactive protein

The complexity of HDL 84

The controversy of triglycerides 87

Hypertension

Risk factor modification in the diabetic patient 89

Glycaemic control

Global risk factor reduction in diabetics 91

The metabolic syndrome 92

Future targets 93

Conclusion

References 94

CHAPTER 6 – MOLECULAR APPROACHES TO REVASCULARISATION IN PERIPHERAL VASCULAR DISEASE

Greg S McMahon, Mark J McCarthy

Introduction 103

Mechanisms of vascular growth

Vasculogenesis

Angiogenesis 104

Neovessel maturation 105

Microvascular network maturation 106

Arteriogenesis

Therapeutic induction of vascular growth 107

Delivery of molecular activators of vascular growth

Angiogenic activators 108

Arteriogenic activators 109

Clinical trials for angiogenic therapy of peripheral vascular disease

Conclusions 110

References

CHAPTER 7 – BIOLOGY OF RESTENOSIS AND TARGETS FOR INTERVENTION

Richard Kenagy

Introduction 115

Mechanisms of restenosis

Thrombosis 116

Remodelling

Intimal hyperplasia 123

Sequence of events after injury

Origin of intimal cells 125

Inflammation 126

Role of ECM production 127

The contribution of specific factors to restenosis

Growth factors/cytokines

Inhibitors 128

Coagulation and fibrinolytic factors 129

Matrix metalloproteinases

Extracellular matrix/receptors

Targets for intervention 130

Intracellular signalling molecules

mTOR and microtubules

Transcription factors

miRNA 131

Inflammation targets

Brachytherapy

Extracellular targets and cell-based therapies

Angiotensin pathway

Cell-based therapies 132

Differential effects on endothelium and SMCs

Delivery devices

Prevention versus reversal of restenosis

Conclusions 133

References 134

CHAPTER 8 – VASCULAR ARTERIAL HAEMODYNAMICS

Michael Lawrence Brown, Kurt Liffman, James Semmens, Ilijia Sutalo

Introduction 153

Laplace's law of wall of tension 154

Newtonian fluid 155

Non-Newtonian fluid

Poiseuille flow 158

Bernoulli's equation

Young's modulus and pulsatile flow 159

Mass conversion 161

Reynold's number

Arterial dissection, collateral circulation and competing flows 163

Shear stress and pressure 164

Forces on graft systems 165

Case 1 – The cylindrical graft 168

Case 2 – The windsock graft

Case 3 – The curved graft 169

Case 4 – The symmetric bifurcated graft

Computational modelling 170

Recent development and future directions 171

Conclusions 172

References 173

CHAPTER 9 – PHYSIOLOGICAL HAEMOSTASIS

Simon McRae

Introduction 177

Primary haemostasis

Platelets

Platelet adhesion

Platelet activation and shape change 179

Platelet aggregation 180

Interactions between primary and secondary haemostasis 181

Secondary haemostasis

The coagulation cascade 182

Initiation 183

Amplification

Propagation 184

Normal inhibitors of coagulation

Fibrinolysis 185

Conclusions 186

References

**CHAPTER 10 –
HYPERCOAGULABLE STATES***Simon McRae***Introduction 189****Classification of thrombophilia**

- Inherited thrombophilia 190
 - Type 1 conditions
 - Antithrombin deficiency
 - Protein C and Protein S deficiency
 - Type 2 conditions 191
 - Factor V Leiden
 - The prothrombin (G20210A) gene mutation
 - FVL/PGM compound heterozygotes
 - Other inherited conditions
- Acquired thrombophilia 192
 - Antiphospholipid antibodies
 - Heparin induced thrombocytopenia
 - Myeloproliferative disorders 193
- Potential reasons for performing thrombophilia testing
- Patients with venous thrombosis and their relatives
 - Providing an understanding of the aetiology of a thrombotic event
 - Determining risk of recurrence and therefore optimal duration of anticoagulation 194
 - Determining the need for primary prophylaxis in asymptomatic family members 195
 - Making decisions regarding the use of the oral contraceptive pill 196
 - Determining the need for thromboprophylaxis during pregnancy
- Patients with arterial thrombosis
- Potential detrimental effects of thrombophilia testing 197
- Conclusion
- References

**CHAPTER 11 – PLATELETS
IN THE PATHOGENESIS OF****VASCULAR DISEASE AND THEIR
ROLE AS A THERAPEUTIC
TARGET***Sandeep Prabhu, Rahul Sharma,
Karlheinz Peter***Introduction 201****Platelet function – Adhesion and activation**

- Platelet adhesion 202
- Platelet activation 203
- Mediators of platelet activation and ‘outside in’ signalling
 - Thrombin and collagen 204
 - Adenosine diphosphate (ADP)
 - Thromboxane A2 (TXA2)
 - Adrenaline 206
- Second messenger systems 207
- Physiological consequences of platelet activation
 - The GP IIb/IIIa receptor and ‘inside-out’ signalling
 - Granule exocytosis 208
 - Activation-induced conformational change of platelets

Platelets and atherosclerosis 209

- Role of platelets in the initiation of the atherosclerosis
- Role of the platelets in the progression of the atherosclerosis
- Role of platelets in vulnerable plaques and plaque rupture

Current and future anti-platelet agents 210

- Aspirin (salicylic acid)
 - Thienopyridines 211
 - Clopidogrel
 - Prasugrel 213
 - Ticlopidine
 - Ticagrelor
 - GPIIb/IIIa Antagonists
 - Other anti-platelet agents and promising new developments 214
- Platelet function testing 215**
- Light-transmission aggregometry

Whole blood aggregometry	217
VerifyNow® Assay	
Flow cytometry	218
References	
 CHAPTER 12 – PATHOGENESIS OF AORTIC ANEURYSMS	
<i>Jonathan Golledge, Guo-Ping Shi, Paul E Norman</i>	
Introduction	227
Differences between thoracic and abdominal aortic aneurysms	228
Summary of current theories and stages of AAA evolution	
Atherosclerosis and AAA	
Immune mechanisms in AAA	229
Extracellular matrix dysfunction	232
Infection	233
Biomechanical forces	
Angiogenesis	
Intra-luminal thrombus	
Extracellular matrix proteolysis	234
Genetics	236
AAA rupture	237
Biomechanical factors in aneurysms rupture	
The role of enzymes in AAA rupture	
Role of intraluminal thrombus in aneurysm rupture	238
Future research	
References	
 CHAPTER 13 – PHARMACOLOGICAL TREATMENT OF ANEURYSMS	
<i>Matthew Thompson, Janet T Powell</i>	
Background	247
Screening programmes	
Pathophysiology	248
Therapeutic strategies	
Beta blockade	
Modification of the inflammatory	
response	249
Non-steroidal anti-inflammatories	
Matrix metalloproteinase (MMP) inhibition	
Anti-chlamydial therapy	250
Drugs acting on the renin/angiotensin axis	
HMG Co-A reductase inhibitors	251
The future – Data from recent experimental studies	
References	
 CHAPTER 14 – PATHOPHYSIOLOGY OF AORTIC DISSECTION AND CONNECTIVE TISSUE DISORDERS	
<i>Mark Hamilton</i>	
Introduction	255
Embryology of thoracic aorta and arch vessels	
Haemodynamics of thoracic compared to abdominal aorta	257
Sizes of normal aorta	
Classification of aortic syndromes	
Acute/Chronic	
DeBakey classification of class 1 dissection – Type 1, 2, and 3	
Stanford classification	258
European task force	
Pathogenesis of thoracic aortic dissection	
Classical thoracic aortic dissection (class 1 dissection)	260
Intramural haematoma (class 2 aortic dissection)	261
Penetrating aortic ulcer (class 4 aortic dissection)	262
Complications of acute aortic syndromes	263
Visceral ischaemia /malperfusion syndromes	
Fate of the false lumen	
Aneurysmal degeneration and rupture	
264	
Connective tissue disorders and acute aortic syndromes	

Marfan syndrome	
Fibrillin and Marfan syndrome	265
The role of transforming growth factor beta in development of the vascular system in health and disease	266
Ehlers-Danlos syndrome	267
Diagnosis of Ehlers-Danlos syndrome	
268	
Loeys-Dietz syndrome	270
Familial thoracic aortic aneurysm disease	
271	
Bicuspid aortic valve	273
Turner's Syndrome	
Summary	274
Reference list	

CHAPTER 15 – BIOMARKERS IN VASCULAR DISEASE

Ian M Nordon, Robert J Hinchliffe

Introduction	277
What is a biomarker?	
Types of biomarkers	
A classical clinical example	278
Potential value of biomarkers in vascular disease	279
Biomarker discovery steps	280
AAA biomarkers	
Circulating extracellular matrix markers	
281	
Matrix-degrading enzymes	283
Proteins associated with thrombosis	
Markers of inflammation	284
Biomarkers of AAA rupture	285
Biomarkers following endovascular repair	
Inflammation	287
Lipid accumulation	
Apoptosis	
Thrombosis	
Proteolysis	288
Challenges in biomarkers discovery	
Future work	
Conclusion	289
References	

CHAPTER 16 – PATHOPHYSIOLOGY AND PRINCIPLES OF MANAGEMENT OF VASCULITIS AND RAYNAUD'S PHENOMENON

Martin Veller

Vasculitides	295
Introduction	
Classification of vasculitides	296
Clinical presentation of vasculitides	
Investigations of vasculitides	
Principles of treatment of vasculitides	
297	
The vasculitides of specific interest to vascular surgeons	298
Giant cell arteritis	
Takayasu's arteritis	299
Thromboangiitis obliterans (Buerger's disease)	300
Behcet's disease	301
Polyarteritis nodosa	302
Vasculitides secondary to connective tissue diseases	303
Systemic lupus erythematosus (SLE)	
Antiphospholipid antibody syndrome (APS)	304
Rheumatoid arthritis	305
Scleroderma	
Infective vasculitides	306
Human immunodeficiency virus (HIV)	
Pathophysiology and principles of Raynaud's phenomenon	307
Prevalence of Raynaud's phenomenon	
308	
Clinical findings in Raynaud's phenomenon	309
Diagnosis of Raynaud's phenomenon	
Prognosis	310
Treatment	
Recommendations	311
References	312

CHAPTER 17 – SIRS, SEPSIS AND

MULTIORGAN FAILURE*Vishwanath Biradar, John Moran***Epidemiology** 315**Historical perspectives and definition** 316**Risk factors for sepsis** 317

Causative agents

Pathophysiology of sepsis

innate immunity and toll-like receptors (TLRs) 319

Proinflammatory response

Coagulation cascade

Multiorgan dysfunction syndrome

(MODS) 320

Epithelial and endothelial dysfunction

Immune suppression and apoptosis

Sepsis, circulatory failure and organ dysfunction

Management 322

Steroids 323

Recombinant human activated protein C (rhAPC) 324

Glucose control 325

Renal replacement therapy

3-hydroxy-3-methylglutaryl-coenzyme reductase inhibitors (HMG-CoA) 326

Other adjuvant therapies in sepsis

Cytokines and anticytokine therapies

Pooled immunoglobulin (IVIG)

Acute respiratory distress syndrome (ARDS) 327

References**CHAPTER 18 – PATHOPHYSIOLOGY OF REPERFUSION INJURY***Prue Cowled, Rob Fitridge***Introduction** 331**Ischaemia**

ATP and mitochondrial function

Gene expression during ischaemia 332

Reperfusion 333

Reactive oxygen species

Eicosanoids 334

Nitric Oxide 335

Endothelin 336

Cytokines

Neutrophil and endothelial interactions 338

Complement activation 340

Tissue destruction 341

Proteases and metalloproteinases

Apoptotic cell death during ischaemia-reperfusion injury

No-reflow phenomenon 342

Therapeutic approaches to IRI

Ischaemic preconditioning

Ischaemic post-conditioning 343

Conditioning effects of volatile anaesthetics

Pharmacological treatments 344

Summary 345**References****CHAPTER 19 – COMPARTMENT SYNDROME***Edward Choke, Robert Sayers, Matthew Bown***Definition** 351**Acute limb compartment syndrome**

Incidence

Anatomy/physiology 352

Aetiology/pathophysiology

Clinical presentation 354

Investigation 355

Treatment 357

Complication of LCS 359

Outcome 360

Acute abdominal compartment syndrome

Incidence 361

Aetiology

Pathological effects of raised intra-abdominal pressure 362

Clinical presentation 363

Investigation

Treatment 364

Complications of surgical decompression

Outcome 367

References 368

CHAPTER 20 – PATHOPHYSIOLOGY OF PAIN

Stephan Schug, Helen Daly, Kathryn Stannard

Introduction 375

Peripheral mechanisms

Nociception/transduction

Conduction 376

Spinal cord mechanisms

Ascending systems 377

Descending control

Pain modulation 378

Peripheral sensation

Central sensitisation in the dorsal horn

Neuropathic pain 379

Mechanisms of neuropathic pain

Peripheral mechanisms

Spontaneous ectopic discharge

Altered gene expression

Spared sensory neurons

Involvement of the sympathetic nervous system 380

Collateral sprouting

Effects of bradykinin

Central mechanisms

Wind up

Central sensitization 381

Central disinhibition

Expansion in receptive field size (recruitment)

Immediate early gene expression

Anatomical re-organisation of the spinal cord

Contribution of glial cells to pain conditions 382

Symptoms of neuropathic pain

Stimulus-dependent pain

Stimulus-independent pain 383

Sympathetically maintained pain (SMP)

Neuropathic pain syndromes

Peripheral neuropathies

Central neuropathies 385

References

CHAPTER 21 – POST-AMPUTATION PAIN

Stephan Schug, Gail Gillespie

Introduction 389

Classification and incidence of post-amputation pain syndromes

Stump pain

Phantom sensation 390

Phantom limb pain

Pathophysiology of post-amputation pain syndromes

Peripheral factors

Spinal factors 391

Supraspinal factors

Current pathophysiological model of post-amputation pain syndromes 392

Prevention of post-amputation pain

Perioperative lumbar epidural blockade

Peripheral nerve blockade 393

NMDA antagonists

Evaluation of the patient with post-amputation pain syndromes

Examination

Therapy of post-amputation pain syndromes 394

Calcitonin

Ketamine

Analgesic and Co-analgesic compounds

Opioids 395

Gabapentin

Clonazepam

Lidocaine

Carbamazepine

Tricyclic antidepressants (TCA)

Selective serotonin reuptake inhibitors

Baclofen

Capsaicin

Symptomatic treatment of pain

components 396

Neuropharmacological therapies

Invasive therapies	
Electroconvulsive therapy (ECT)	
Nerve blockade	
Spinal cord stimulation	
Implantable intrathecal delivery systems	
Dorsal root entry zone (DREZ) lesions	
Psychological therapy	397
Future aims	
References	
 CHAPTER 22 – TREATMENT OF NEUROPATHIC PAIN	
<i>Stephan Schug, Kathryn Stannard</i>	
Introduction	401
Principles of treatment	
Pharmacological treatment	402
Opioids	
Recommendations for clinical use of opioids	
Tramadol	
Mechanism of action	
Efficacy	403
Adverse effects	
Recommendations for clinical use of tramadol in neuropathic pain	
Antidepressants	
Tricyclic antidepressants (TCAs)	
Mechanism of action	404
Adverse effects	
Selective serotonin re-uptake inhibitors (SSRIs)	
Serotonin/Noradrenaline reuptake inhibitors (SNRIs)	405
Recommendations for clinical use of antidepressants as analgesics	
Anticonvulsants	
Mechanism of action	406
Individual medications	
Clonazepam	
Gabapentin	
Pregabalin	407
Carbamazepine	
Sodium valproate	408
Phenytoin	
Lamotrigene	
Recommendations for clinical use of anticonvulsants as analgesics	
Local anaesthetics and antiarrhythmics	
409	
Mechanism of action	
Lignocaine	
Mexiletine	
Recommendations for clinical use of lignocaine and mexiletine in neuropathic pain	
N-methyl-D-aspartate-receptor antagonists (NMDA)	
Ketamine	410
Other NMDA antagonists	
Miscellaneous compounds for systemic use	
Clonidine	
Efficacy	
Baclofen	
Levodopa	411
Cannabinoids	
Topical treatments	
Lignocaine 5% medicated plaster	
Capsaicin	412
Mechanism of action	
Efficacy	
Non-pharmacological therapy	
Transcutaneous electrical nerve stimulation (TENS)	
Spinal cord stimulation (SCS)	413
Sympathetic nerve blocks	
Neurosurgical destructive techniques	
Cognitive behavious therapy	
References	414
 CHAPTER 23 – PRINCIPLES OF WOUND HEALING	
<i>Gregory Schultz, Gloria Chin, Lyle Moldawer, Robert Diegelmann</i>	
Introduction	423
Phases of acute wound healing	
Haemostasis	

Inflammation 426	Varicose veins 453
Neutrophils 427	Valvular abnormalities
Macrophages 428	Muscle pump failure 455
Proliferative phase 429	Venous recirculation
Fibroblast migration 430	Recurrent varicose veins
Collagen and extracellular matrix production	New varicose veins
Angiogenesis 431	Persistent varicose veins
Granulation 432	True recurrent varicose veins 456
Epithelialization	Cellular and molecular biology of varicose veins
Remodelling 433	Conclusion 457
Summary of acute wound healing 435	References
Comparison of acute and chronic wounds	
Normal and pathological responses to injury	
Biochemical differences in the molecular environments of healing and chronic wounds 436	
Biological differences in the response of chronic wound cells to growth factors 439	
From bench to bedside	
Role of endocrine hormones in the regulation of wound healing	
Molecular basis of chronic non-healing wounds	
Chronic venous stasis ulcers 441	
Pressure ulcers	
Future concepts for the treatment of chronic wounds 442	
Bacterial biofilms in chronic wounds 443	
Conclusion 445	
References	
CHAPTER 24 – PATHOPHYSIOLOGY AND PRINCIPLES OF MANAGEMENT OF VARICOSE VEINS	
<i>Andrew Bradbury</i>	
Introduction 451	
Anatomy	
Histology 452	
Physiology	
CHAPTER 25 – CHRONIC VENOUS INSUFFICIENCY AND LEG ULCERATION: PRINCIPLES AND VASCULAR BIOLOGY	
<i>Michael Stacey</i>	
Definitions 459	
Chronic venous insufficiency	
Leg ulceration	
Assessment of cause of leg ulceration 460	
Epidemiology 461	
Pathophysiology	
Venous abnormality	
Effect of ambulatory venous hypertension on the tissues in the leg 463	
Influence of venous disease on the wound healing process 465	
Genetic associations with venous ulceration 466	
Assessment of venous function 467	
Treatment of venous ulceration	
Compression therapy	
Dressings 468	
Surgery	
Prevention of venous ulcer recurrence 470	
Sclerotherapy and other techniques to obliterate surface and perforating veins	
Other therapies 471	
References	

CHAPTER 26 – PATHOPHYSIOLOGY AND PRINCIPLES OF MANAGEMENT OF THE DIABETIC FOOT

David Armstrong, Timothy Fisher, Brian Lepow, Matthew White, Joseph Mills

Introduction 475

Pathophysiology of the diabetic foot 476

Neuropathy

Structural abnormalities/gait abnormalities

Angiopathy 478

Diagnosis

History and rapid visual screening

Neurological examination 479

Monofilament testing

Vibration testing

Dermatologic examination 480

Anatomy of occlusive disease – vascular examination

Prediction of wound healing: assessment of perfusion 481

Arterial imaging

Soft tissue imaging 482

Classification systems 483

Diabetes mellitus foot risk classification

University of Texas wound classification system

Clinical problems and principles of management 484

Ulceration

Epidemiology and risk factors

Offloading

Non-vascular surgical treatment 485

Class I – Elective 486

Class II – Prophylactic

Class III – Curative

Class IV – Emergency (urgent)

Post-operative management

Infections 487

Charcot arthropathy

Prevention 490

Conclusion 492

References

CHAPTER 27 – LYMPHOEDEMA – PRINCIPLES, GENETICS AND PATHOPHYSIOLOGY

Matt Waltham

Introduction 497

Classification of lymphoedema

Classification of primary lymphoedema 498

The genetics of lymphangiogenesis in primary lymphoedema 500

Milroy's disease

Lymphoedema – distichiasis syndrome 501

Hypotrichosis – lymphoedema – telangiectasia syndrome 502

Meige disease (primary non-syndromic lymphoedema)

Other primary lymphoedema disorders 503

Structure and development of the lymphatic circulation

Clinical aspects of lymphoedema 505

Summary

References

CHAPTER 28 – GRAFT MATERIALS PAST AND FUTURE

Mital Desai, George Hamilton

The pathophysiology of graft healing 511

The peri-anastomotic area

Healing of prosthetic grafts 512

The healing process of the anastomosis

Graft porosity and permeability

Physical properties of prosthetic materials 514

Tubular compliance

Anastomotic compliance mismatch

The compliance hypothesis of graft failure

Synthetic grafts 515

Newer developments of Dacron grafts

Modifications and newer developments of PTFE grafts 517

Polyurethane grafts

Newer developments of polyurethane vascular grafts	518	CHAPTER 29 – PATHOPHYSIOLOGY OF VASCULAR GRAFT INFECTIONS
Biological vascular grafts	519	<i>Mauro Vicaretti</i>
Newer developments of biological vascular grafts	520	Introduction 537
Prosthetic graft modifications		Natural history of prosthetic vascular graft infections
Modifications to reduce graft infection		Mechanism of graft contamination at operation 538
Modifications to improve patency	521	Pathogenesis of graft infections
Nanocomposite grafts		Bacteriology of vascular graft infections
Endothelial cell seeding	522	Investigations for detection of prosthetic graft infections 539
Single stage seeding		History and physical examination
Two stage seeding		Laboratory investigations
Vascular tissue engineering		Diagnostic imaging 540
Non-degradable polymer and cell seeding		Management of prosthetic graft infections
523		Prevention
Bioresorbable and biodegradable polymers		Reduction of prosthetic vascular graft infection with rifampicin bonded gelatin sealed Dacron 541
Combined bioresorbable and tissue engineered grafts	524	Established infection
Mechanical conditioning of seeded vascular cells		Antibiotic therapy
Alternative scaffolds		Operative management
Tissue-engineered grafts	525	Conclusion 542
Graft materials for aortic endografts	526	References
The future		
References	527	

Acknowledgements

The Editors gratefully acknowledge the outstanding contributions of each Author involved in this reference book. We would also like to acknowledge the invaluable efforts of Ms Sheona Page who has worked tirelessly on this project. We would also like to thank Prue Cowled PhD and Ms Cayley Wright for their assistance.

Abbreviation List

a1-PI	a1-protease inhibitor
5-HT	5-Hydroxytryptamine/Serotonin
AAA	Abdominal aortic aneurysm
AAS	Acute aortic syndrome
AAV	Adeno-associated viruses
ACE	Angiotensin converting enzyme
ACS	Acute coronary syndrome
ACS	Abdominal compartment syndrome
ACTH	Adrenocorticotrophic hormone
ADAMTS	A disintegrin and metalloproteinase with thrombospondin motifs
ADP	Adenosine diphosphate
AIDS	Acquired immune deficiency syndrome
ALI	Acute lung injury
AMP	Adenosine monophosphate
AMPA	α -amino-3 hydroxy-5-methylisoxazole
ANA	Anti-nuclear antibody
ANCA	Anti-neutrophil cytoplasmic antibody
AOD	Aortic occlusive disease
AP1	Activated protein 1
APC	Activated protein C
APC	Antigen presenting cell
APLAS	Antiphospholipid antibody syndrome
ApoAI	Apolipoprotein AI
ApoE	Apolipoprotein E
APS	Antiphospholipid antibody syndrome
APTT	Activated partial thromboplastin time

ARDS	Acute respiratory distress syndrome
AT	Antithrombin
ATP	Adenosine triphosphate
AVP	Ambulatory venous thrombosis
β 2-GPI	β 2-glycoprotein Ib
bFGF	Basic fibroblast growth factor
BKCa	Large conductance calcium activated potassium channel
BMPs	Bone morphogenetic proteins
BMS	Bare metal stent
CAD	Coronary artery disease
CaM	Calmodulin
CAM	Cell adhesion molecule
cAMP	Cyclic adenosine monophosphate
CCK	Cholecystokinin
cGMP	Cyclic guanine monophosphate
CD	Cluster of differentiation
CD40L	Cluster of differentiation 40 ligand
CEA	Carotid endarterectomy
CETP	Cholesteryl ester transfer protein
CFD	Computational fluid dynamics
CG	Cationized gelatin
CGRP	Calcitonic gene regulated peptide
CHD	Coronary heart disease
CI	Confidence interval
CIMT	Carotid intimal-media thickness
c-JNK	c-Jun N-terminal kinase
CK-MB	Creatinine kinase (Myocardial specific)
CNCP	Chronic noncancer pain
cNOS	Constitutive nitric oxygen synthase enzyme
COX-1	Cyclooxygenase-1
COX-2	Cyclooxygenase-2
CROW	Charcot restraint orthotic walker
CRRT	Continuous renal replacement therapy

CRP	C-reactive protein
CRPS	Complex regional pain syndromes
CT	Computational tomography
CTA	Computed tomographic angiography
CTD	Connective tissue disorders
CTGF	Connective tissue growth factor
CYP	Cytochrome P450
CVD	Cardiovascular disease
CVI	Chronic venous insufficiency
DAG	Diacylglycerol
DES	Drug-eluting stent
DRG	Dorsal root ganglion
DNA	Deoxyribonucleic acid
DSA	Digital subtraction arteriography
DTS	Dense tubular system
DVT	Deep vein thrombosis
EC	Endothelial cell
ECM	Extracellular matrix
EDCF	Endothelium-derived contracting factor
EDH	Endothelium-dependent hyperpolarisation
EDS	Ehlers-Danlos syndrome
EET	Epoxyeicosatrienoic acids
ELAM-1	Endothelial-leukocyte adhesion molecule-1
ELG	Endoluminal grafts
ELISA	Enzyme linked immunosorbent assay
E_K	Equilibrium potential
E_M	Membrane potential
eNOS	Endothelial nitric oxide synthase enzyme
EPC	Endothelial progenitor cells
EPCR	Endothelial protein C receptor
ePTFE	Expanded polytetrafluoroethylene
ERK	Extracellular signal-regulated kinase
ESR	Erythrocyte sedimentation rate

ET	Essential thrombocytosis
ET-1	Endothelin 1
EVAR	Endovascular aortic aneurysm repair
EVLA	Endovenous LASER ablation
FDA	Food and drug administration
FDPs	Fibrin degradation products (soluble)
FGF	Fibroblast growth factor
FGF-2	Fibroblast growth factor 2
FMN	Flavin mononucleotide
FVL	Factor V Leiden
GABA	Gamma-aminobutyric acid
GABA B	Gamma-aminobutyric acid subtype B
G-CSF	Granulocyte colony stimulating factor
GMCSF	Granulocyte-macrophage colony stimulating factor
GP	Glycoprotein
GPCR	G-protein coupled receptor
GSV	Great saphenous vein
HDL	High density lipoprotein
HDL-C	High density lipoprotein cholesterol
HIF	Hypoxia inducible factor
HIT	Heparin induced thrombocytopenia
HIV	Human immunodeficiency virus
HLA	Human leukocyte antigen
HMG Co-A	Hydroxymethylglutaryl coenzyme-A
HMW	High molecular weight
HPETE	Hydroperoxyeicosatetraenoic acid
HETE	Hydroxyeicosatetraenoic acids
HR	Hazard ratio
hsCRP	High-sensitive C-reactive protein
HSP	Heat shock protein
HUV	Human umbilical vein
IAH	Intra-abdominal hypertension

IAP	Intra-abdominal pressure
IAPP	Intra-abdominal perfusion pressure
ICAM-1	Inter-cellular adhesion molecule-1
ICAM-2	Inter-cellular adhesion molecule-2
ICP	Intra-compartmental pressure
ICU	Intensive care unit
IFN	Interferon
IGF-1	Insulin-like growth factor-1
IHD	Ischemic heart disease
IL	Interleukin
IL-1	Interleukin-1
IL-1 α	Interleukin-1 alpha
IL1- β	Interleukin-1 beta
IL-6	Interleukin-6
IL-8	Interleukin-8
ILT	Intraluminal thrombus
IKCa	Intermediate conductance calcium-activated potassium channels
IMH	Intramural haematoma
IMP	Inosine monophosphate
iNOS	Inducible nitric oxide synthase enzyme
IP(3)	1,4,5-inositol triphosphate
IRI	Ischemia reperfusion injury
IVIG	Intravenous pooled immunoglobulin
IVUS	Intravascular ultrasound
KGF	Keratinocyte growth factor
KGF-2	Keratinocyte growth factor-2
LAP	Latency associated peptide
LCS	Limb compartment syndrome
LDL	Low density lipoprotein
LDS	Loeys-Dietz syndrome
LLC	Large latent complex
LEC	Lymphatic endothelial cells

LFA-1	Lymphocyte function-associated antigen-1
LO	Lipoxygenase
LOX	Lysyl oxidase
LOPS	Loss of protective sensation
LPA	Lysophosphatidic acid
LPS	Lipopolysaccharide
LTA	Lipoteichoic acid
LTGFBP	Latent TGF binding protein
MAC-1	Macrophage-1 antigen
MAPK	Mitogen activated protein kinase
MCP-1	Monocyte chemoattractant protein-1
M-CSF	Macrophage-colony stimulating factor
MFS	Marfan syndrome
MHC	Major histocompatibility
MI	Myocardial infarction
MIP-1	Macrophage inflammatory protein-1
MLC ₂₀	Myosin light chain ₂₀
MLCK	Myosin light chain kinase
MLCP	Myosin light chain phosphatase
MMP	Matrix metalloproteinase
MODS	Multiple organ dysfunction syndrome
MRA	Magnetic resonance angiography
MRI	Magnetic resonance imaging
mRNA	Messenger RNA
MRSA	Methicillin resistant <i>Staphylococcus aureus</i>
MRSE	Methicillin resistant <i>Staphylococcus epidermidis</i>
MRTA	Magnetic resonance tomographic angiography
MTHFR	Methylenetetrahydrofolate reductase
MT-MMP	Membrane-type MMP
MVPS	Mitral valve prolapse syndrome
NADPH	Nicotinamide adenine dinucleotide phosphate
NGF	Nerve growth factor

NF κ B	Nuclear factor kappa B
NiT	Nitinol
NJP	Non-junctional perforators
NMDA	N-methyl-D-aspartate
NNH	Number needed to harm
NNT	Number needed to treat
NO	Nitric oxide
NOS	Nitric oxide synthase enzyme
NSAID	Non-steroidal anti-inflammatory drug
NV	Neovascularisation
OCP	Oestrogen/progesterone contraceptive pill
OPN	Osteopontin
OPG	Osteoprotegerin
OR	Odds ratio
OxLDL	Oxidised low density lipoprotein
PAD	Peripheral arterial disease
PAF	Platelet activating factor
PAI	Plasminogen activator inhibitor
PAI-1	Plasminogen activator inhibitor-1
PAR	Protease activated receptor
PAR-1	Protease activated receptor-1
PAR-4	Protease activated receptor-4
PAU	Penetrating aortic ulcer
PC	Protein C
PCA	Poly (carbonate-urea) urethane
PCI	Percutaneous coronary intervention (angioplasty)
PCWP	Pulmonary capillary wedge pressure
PDGF	Platelet-derived growth factor
PDGF β	Platelet-derived growth factor- β
PDS	Polydioxanone
PECAM-1	Platelet-endothelial cell adhesion molecule-1
PEDF	Pigment epithelium-derived factor
PES	Paclitaxel-eluting stent

PET	Positron emission tomography
PF4	Platelet factor 4
PGI ₂	Prostacyclin
PGG ₂	Prostaglandin G ₂
PGH ₂	Prostaglandin H ₂
PGEI ₂ /PGI ₂	Prostaglandin I ₂
PGN	Peptidoglycan
PHN	Postherpetic neuropathy
PHZ	Para-anastomotic hyper-compliant zone
PI3K	Phosphatidylinositol 3-kinase
PIP2	Phosphatidylinositol 4,5-bisphosphate
PLC	Phospholipase C
PLOD	Procollagen lysyl hydroxylase
PMCA	Plasma membrane Ca ²⁺ APTases
PMN	Polymorphonuclear leukocyte
POSS	Polyhedral oligomeric silsesquioxanes
PPAR	Peroxisomal proliferation activating receptor
PPI	Proton pump inhibitor
PRV	Polycythaemia rubra vera
PS	Protein S
PSGL-1	P-selectin glycoprotein ligand-1
PT	Prothrombin time
PTCA	Percutaneous coronary angioplasty
PTFE	Polytetrafluoroethylene
PTS	Post-thrombotic syndrome
PUFA	Polyunsaturated fatty acid
PVI	Primary valvular incompetence
rAAA	Ruptured AAA
Rac	Ras activated cell adhesion molecule
RANTES	Regulated upon activation, normal T cell expressed and secreted
RAS	Renin angiotensin system
RCT	Randomised controlled trial

RF	Rheumatoid factor
RFA	Radiofrequency ablation
rhAPC	Recombinant human activated protein C
RNA	Ribonucleic acid
ROS	Reactive oxygen species
RR	Relative risk
RSD	Reflex sympathetic dystrophy
S1P	Sphingosine-1-phosphate
SAPK	Stress-activated protein kinase
SCF	Stem cell factor
SCS	Spinal cord stimulation
ScvO2	Superior vena cava venous oxygen saturation
SDF-1	Stromal-cell-derived factor-1
SERCA	Sarco/endoplasmic reticulum CaATPases
SEP	Serum elastin peptides
SES	Sirolimus-eluting stent
SEPS	Subfascial endoscopic perforator surgery
SFA	Superficial femoral artery
SFJ	Sapheno-femoral junction
SIRS	Systemic inflammatory response syndrome
SKCa	Small conductance calcium-activated potassium channels
SLE	Systemic lupus erythematosus
SMA	Smooth muscle alpha actin
SMC	Smooth muscle cell
SMP	Sympathetically maintained pain
SNARE	Soluble N-ethylmaleimide-sensitive factor activating protein receptors
SNP	Single nucleotide polymorphisms
SNRI	Serotonin/Noradrenaline reuptake inhibitors
SPJ	Sapheno-popliteal junction
SPP	Skin perfusion pressure
SR	Sarcoplasmic reticulum
SSRIs	Selective serotonin re-uptake inhibitors
SSV	Small saphenous vein

SVT	Superficial thrombophlebitis
STIM1	Stromal interacting molecule 1
T α CE	TNF α converting enzyme
TAAD	Thoracic aortic aneurysm disease
TAD	Thoracic aortic dissection
TAFI	Thrombin-activatable fibrinolysis inhibitor
Tc-99 MDP	Technetium-99 methylene diphosphonate
TCA	Tricyclic antidepressant
TCC	Total contact cast
TCR	T-cell receptor
TENS	Transcutaneous electrical nerve stimulation
TF	Tissue factor
TFPI	Tissue factor pathway inhibitor
TGF	Transforming growth factor
TGF- α	Transforming growth factor-alpha
TGF- β	Transforming growth factor-beta
TGL	Triglycerides
Th	T helper
TIA	Transient ischemic attack
TIMP	Tissue inhibitors of metalloproteinase
TLR	Toll-like receptors
TNF	Tumour necrosis factor
TNF- α	Tumour necrosis factor-alpha
tPA	Tissue-type plasminogen activator
TRP	Transient receptor potential
TRPC	Transmembrane receptor potential canonical
TRPV1	Transmembrane receptor potential Vanilloid-type
TXA2	Thromboxane A2
uPA	Urokinase
UT	University of Texas
VCAM	Vascular cell adhesion molecule
VCAM-1	Vascular cell adhesion molecule-1
VEGF	Vascular endothelial growth factor

VEGF-R	Vascular endothelial growth factor receptor
VIP	Vasoactive intestinal peptide
VLA-1	Very late activating antigen-1
VOCC	Voltage operated calcium channels
VPT	Vibratory perception threshold
VSMC	Vascular smooth muscle cells
VTE	Venous thromboembolism
VV	Varicose veins
vWF	von Willebrand factor
XO	Xanthine oxidase

20 • Pathophysiology of Pain

STEPHAN A. SCHUG, HELEN C. S. DALY,
KATHRYN J.D. STANNARD

School of Medicine and Pharmacology, University of Western Australia,
Royal Perth Hospital, Perth, WA.

INTRODUCTION

Pain is defined as an unpleasant sensory and emotional experience associated with actual or potential tissue damage.¹

The mechanism by which a damaging stimulus in the body is perceived as painful by the brain is a complex one which is not yet fully understood. The complexity of the process results from the nervous system not being a 'hard wired' system, but exhibiting plasticity that enables it to modify its function under different conditions.

As shown by the definition, pain serves the purpose to prevent tissue damage and protect the body while it is healing. Under certain conditions, pain can become maladaptive and persist as chronic pain. This pain serves no protective function and is described as pathological pain as opposed to physiological pain;² it is then no longer a symptom of another disease, but a disease in its own right.³ Another term for pathological pain has been suggested recently: dysfunctional pain.⁴

In order to adequately treat physiological, but even more pathological pain, an understanding of pain mechanisms is required.

PERIPHERAL MECHANISMS

Nociception/Transduction

Painful stimuli are detected by nociceptors, which are free nerve endings located in tissues and organs. They have high thresholds and, under normal circumstances, only respond to noxious stimuli.

There are two distinct types of nociceptors

- High threshold mechanoreceptors which stimulate small myelinated A δ -fibres and transmit a well-localised sharp or pricking sensation that lasts as long as the stimulus.
- Polymodal nociceptors that stimulate small unmyelinated slowly conducting C fibres. As well as responding to mechanical stimuli they are activated by thermal and chemical stimuli e.g. hydrogen ions, potassium ions, bradykinin, serotonin, adenosine triphosphate and prostaglandins.

The ion channels for noxious stimuli have been partially identified; the transient receptor potential (TRP) family of these ion channels and in particular the vanilloid-type

TRP 1 (TRPV1) have been studied in most detail.⁵ This receptor is sensitive to higher temperatures, acidity and capsaicin, an exogenous ligand (extract of chilli pepper) and receptors like this one are currently investigated as therapeutic targets for pain therapy.

Nerve growth factor (NGF) is also involved in the transduction process, as it binds to its receptor TrKa and thereby triggers increased transduction in pain states, in particular inflammatory pain. A monoclonal antibody against NGF, tanezumab, has shown very promising effects in early stage trials in osteoarthritis and chronic low back pain.⁶

Conduction

Voltage-gated sodium channels mediate conduction along primary sensory afferents. As for all other impulses throughout the body, action potential propagation is dependent on these channels. There are two types of sodium channels, differentiated by their sensitivity to tetrodotoxin. Both types are present in nociceptive neurons, with the tetrodotoxin-resistant type only present in nociceptors, which makes it a potential target for novel analgesics. Further research has identified two such sodium channels, labelled NaV1.7 and NaV1.8, which seem to have a specific role in pain modulation.⁷ Mutations of these channels are linked to congenital insensitivity to pain and erythromyalgia and attempts are made to identify blockers of these channels, which might be therapeutic in chronic or neuropathic pain.

Nociceptors also have voltage-gated calcium channels, which are found on the presynaptic membrane and are involved in neurotransmitter release at the dorsal horn. These are modulated by alpha-2-delta compounds such as gabapentin and pregabalin, new first-line treatments of neuropathic pain and central sensitisation.⁸

Pain is transmitted by primary afferents, which have their cell bodies in the dorsal root ganglion (DRG). They terminate in the dorsal horn of the spinal cord. The dorsal horn cells are divided into specific regions or laminae called Rexed's laminae with lamina I being the most superficial.⁹

- A δ -fibres are fast conducting and transmit the first sharp pain on initial stimulation. They terminate mainly in lamina I, but also send some fibres to lamina V of the dorsal horn where they synapse with second order neurones. They contain the neurotransmitter L-glutamate.
- C fibres are unmyelinated slow conducting fibres which transmit a less well localised persistent aching pain that lasts after the initial stimulus has gone. They terminate in lamina II of the dorsal horn. As well as glutamate they contain several other neurotransmitters including neuropeptides, such as substance P, and calcitonin gene-related peptide (CGRP), cholecystokinin, brain-derived neurotrophic factor and glial-derived neurotrophic factor. C fibres express several presynaptic receptors that modulate transmitter release. These include cholecystokinin (CCK), opioid and gamma-aminobutyric acid subtype B (GABA B) receptors. Apart from the CCK receptor, they inhibit the release of transmitter.
- A β -fibres conduct low intensity mechanical stimuli which convey touch and not pain, however in chronic pain states they are involved in the transmission of pain. They terminate deeper in the dorsal horn in laminae III-VI.

SPINAL CORD MECHANISMS

Primary sensory afferents terminate in the spinal cord where they synapse with cells

of the dorsal horn. Nociceptive specific neurons are located mainly in laminae I and II but also lamina V and respond only to noxious inputs under normal conditions.

There are a number of different cells involved in the relay of painful stimuli including nociceptive specific cells and wide dynamic range neurons. Wide dynamic range neurons are located mainly in lamina V, but also in III and IV to a lesser extent, where they respond to stimuli from A β -, A δ - and C-fibres.⁹

The cells of the dorsal horn involved in nociception express a number of receptors.

- AMPA (a-amino-3-hydroxy-5-methylisoxazole) receptors which bind glutamate.
- NMDA (N-methyl-D aspartate) receptors which also bind glutamate, neurokinin receptors NK-1 which bind substance P.
- GABA-A receptors which are ligand-gated calcium channels that hyperpolarize the cell and reduce responsiveness to stimulation.
- Voltage-gated calcium channels.
- Glycine receptors that provide an inhibitory function

The ability to detect a potentially damaging noxious stimulus is mediated by glutamate acting on the AMPA receptor following stimulation of A δ -fibres. The other receptors and neurotransmitters are involved in the modulation of the response.

When a high intensity noxious stimulus arrives at the dorsal horn via C-fibres, initially glutamate is released which acts via the AMPA receptor. As stimulus intensity increases, then other neurotransmitters are released such as Substance P. Slow post-synaptic currents are set up which are mediated by a number of receptors including the NMDA receptor. These are also involved in the modulation of the pain response.¹⁰

Ascending systems

Noxious information is conveyed from the dorsal horn to the brain via several ascending tracts in the spinal cord. The majority of the wide dynamic range neurons and nociceptive specific neurons are conveyed anterolaterally in three pathways:¹¹

- The spinothalamic tract: Its fibres cross over to the contralateral side and pass through the brainstem to nuclei in the thalamus, finally terminating in the somatosensory cortex where pain is perceived and localised.
- The spinoreticular tract: It terminates in the reticular formation and has projections, which terminate in the pons, medulla and periaqueductal grey matter. It is involved in descending inhibition of pain.
- The spinomesencephalic tract: It is also involved in the modulation of descending control.

Descending control

The dorsal horn receives inputs from higher centres that modulate the response to nociceptor input.¹²

The descending control of output from the dorsal horn comes mainly from areas in the brainstem, namely the periaqueductal grey matter, the raphe nuclei and the locus coeruleus.¹³ Inhibitory tracts descend in the dorsolateral fasciculus and synapse in the dorsal horn. The key neurotransmitters involved are noradrenaline and serotonin. Noradrenaline acts via post synaptic α -2 receptors, the action of serotonin is less specific. Endogenous opioids are also involved in descending inhibition at a spinal and supraspinal level.¹³ These endorphins and enkephalins acting via the descending system are thought to be responsible for the analgesia induced by stress.

As well as descending control from the brainstem, nociceptive impulses are also attenuated by input via A β -fibres (transmitting information on touch), which is the basis for the use of Transcutaneous Electrical Nerve Stimulation (TENS) for analgesia, but also for simply rubbing a hurting body part. This observation formed the basis for the initial gate-control theory of pain.¹⁴

PAIN MODULATION

The above description of pain explains the initial sensation of pain immediately following injury, however it does not explain the more complex phenomena associated with pathological pain due to neuroplastic changes.

These phenomena have a number of different causal mechanisms, which occur initially in the periphery, but later mainly in the dorsal horn as the main site modulation of painful stimuli.

Peripheral sensitisation

Tissue injury results in the release of inflammatory mediators, such as bradykinin, histamine, K+, H+, 5-Hydroxytryptamine (5-HT), ATP and nitric oxide from damaged cells.¹⁵ Breakdown of arachidonic acid by cyclo-oxygenase produces leukotrienes and prostaglandins. Immune cell activation results in the release of further mediators including cytokine and growth factors. These mediators provide an ‘inflammatory soup’ which produces a painful area of primary hyperalgesia. These inflammatory mediators spread into the tissues surrounding the initial area of injury to produce an area of secondary hyperalgesia.

They act either by stimulating nociceptors themselves or by acting via inflammatory cells to stimulate release of additional pain

inducing agents. They also modify the response of primary afferents to subsequent stimuli either by changing the sensitivity of the receptors or by modulating the voltage-gated ion channels. For example, after tissue and nerve injury, N-type calcium channels become more active resulting in greater release of glutamate in the spinal cord.¹⁶ The magnitude of the current generated by sensory-neuron specific sodium channels is also increased.

Chronic inflammation and also nerve injury has an effect on the presence and distribution of voltage-gated sodium channels, which can become concentrated in areas of injury and produce ectopic discharges. Sensory-neurone-specific sodium channels have a significant role in chronic pain states. Studies have shown them to become concentrated in neurones proximal to a site of nerve injury and play a role in the hyperalgesia and allodynia of chronic pain states.⁹ In addition, NGF binding to TrKa receptors increases peripheral sensitivity as discussed before.⁶

Not all sensory neurons are active all the time and this peripheral sensitisation will recruit ‘dormant’ nociceptors, thus increasing the receptive fields of dorsal horn neurons and increasing the intensity and the area of pain.¹⁷

Central sensitisation in the dorsal horn

Central sensitisation is an increase in the excitability of the dorsal horn so that the dorsal horn cells have a lower threshold and respond to low intensity stimuli that are not usually painful. It also results in a greater response to supra threshold stimuli thus producing the symptoms of allodynia and hyperalgesia.

There are several mechanisms, which occur at the dorsal horn and contribute to

chronic pathological pain states by central sensitisation. These will be discussed in the context of neuropathic pain, as they are most relevant there.

NEUROPATHIC PAIN

Neuropathic pain arises following disease or injury to nerves from a number of aetiologies eg, ischaemic, traumatic, infection. Characteristics of neuropathic pain include spontaneous stimulus-independent pain and pain that is stimulus dependent and exhibits the features of allodynia and hyperalgesia. There are a variety of different mechanisms responsible for the generation of symptoms, which may be quite different from patient to patient.¹⁸

Mechanisms of neuropathic pain

The pathophysiology of neuropathic pain involves central and peripheral mechanisms and is in principle a 'maladaptive response of the nervous system to damage'.⁴ Usually more than one mechanism may be involved and producing a unifying hypothesis for all neuropathic pain states is inappropriate.¹⁹

Peripheral mechanisms

Electrophysiological evidence over the last 25 years shows that activity in sensory neurones after injury is necessary for the development of neuropathic symptoms. Some proposed mechanisms are:

Spontaneous ectopic discharge

Normal primary afferent neurones require the input of a stimulus in order to reach firing potential. It has been shown that after a nerve injury spontaneous firing in the afferent neurone occurs. A and C fibres have been shown to demonstrate oscillatory activity resulting in ectopic firing. Cross excitation of other neurones increases this effect. These

phenomena may be particularly relevant to the development of hyperalgesia, allodynia and chronic pain after nerve injuries.

Reorganisation of expression of ion channels in the peripheral nerves is responsible for the ectopic discharge. Both sodium and calcium channels have been shown to be involved with their altered expression increasing the excitability of neurones. The afferent barrage provided by spontaneous discharge from neurones provides a constant input to the central nervous system that may induce central sensitisation.²⁰

Altered gene expression

Damaged peripheral sensory neurones undergo Wallerian degeneration and lose contact with peripheral targets and the supply of neurotrophic factors. The sensory neurones undergo altered gene expression, the result of which is a change in the type and level of neurotransmitters released in the spinal cord.²¹ For example, some A-β fibres appear to release transmitters normally associated with nociceptors such as substance P. This seems to contribute to central sensitisation.²² A change in gene expression also results in either up or down regulation of ion channels, in particular different types of sodium channel involved in ectopic spontaneous activity.

Spared sensory neurons

Changes have also been found in uninjured sensory fibres that are along side those with a lesion. They frequently show the opposite gene expression changes from their damaged neighbours; possibly due to increased bioavailability of neurotrophic factors. This can result in increased activity in the spared afferents, although the exact mechanism is not understood.²¹

Involvement of the sympathetic nervous system

Some patients exhibit neuropathic pain that is dependent on activity in the sympathetic nervous system.²³ After a peripheral nerve injury, a coupling develops between the sympathetic nervous system and the sensory nervous system. Axons involved develop increased α -adrenoceptors and therefore have an exaggerated response to circulating catecholamines. Morphological changes to the nerve follow with sympathetic axons sprouting into the dorsal root ganglion forming baskets around the cell bodies of sensory neurones. These changes lead to sympathetically maintained pain. Evidence for a sympathetic component to a patient's pain include sympathetically maintained, often unilateral limb pain, oedema, vaso-motor and sudomotor asymmetries.

Collateral sprouting

Sprouting of fibres from sensory axons in the skin has been shown to occur in denervated areas, for example after crush injuries. However this does not occur in proportion to the degree of neuropathic pain experienced and is likely to be a small if at all significant factor in its pathophysiology.

Effects of bradykinin

This main plasma kinin, a vasodilator peptide, is involved in hyperalgesia associated with inflammatory pain, with a change in expression of its binding sites within the dorsal root ganglion after nerve injury.

Central mechanisms

The central mechanisms potentially involved in the generation of neuropathic pain are thought to result in neuroplastic changes in the CNS. A phenomenon termed central sensitisation occurs after peripheral nerve injury. Central sensitisation changes the way the neurones respond to subsequent inputs.⁴

This may result in spontaneous ongoing pain and abnormally evoked pain (allodynia and hyperalgesia).¹⁷ The mechanisms that are thought to be responsible occur primarily in the dorsal horn.

Wind-up

The term wind up describes the altered response of the dorsal horn neurones to repeated input from C-fibres.^{10,17} Following brief, repetitive C-fibre stimulation, the dorsal horn cells respond in a linear fashion. However if the stimulus continues, further C-fibre activation produces an amplified response in the dorsal horn to the same intensity of stimulus.

This phenomenon is mediated by the NMDA receptor. Activation by sustained C fibre input leads to opening of the channel, an increased intracellular calcium concentration and an increased response to glutamate. Glutamate is the main excitatory neurotransmitter released from primary afferent neurones that acts at postsynaptic receptors. The NMDA receptor in its resting state is blocked by magnesium which is released when the cell is depolarised thus opening the channel in the receptor and allowing an influx of sodium and calcium and further depolarisation. When a painful stimulus arrives at the dorsal horn, the cells are initially depolarised by glutamate acting at the AMPA receptor thus allowing removal of the magnesium block. Once the stimulus is removed, the dorsal horn cells continue to fire for several seconds.

There is potential for this to be modified pharmacologically and a number of studies suggest that NMDA antagonists may prevent these phenomena and prevent hyperalgesia.¹⁰

Wind up is relatively short lived (seconds to minutes), whereas central sensitisation persists so the exact relationship remains unclear.

Central sensitization

Central sensitisation is also mediated by the NMDA receptor. Under conditions of prolonged C-fibre activation, depolarisation of the dorsal horn cells causes the NMDA receptor to lose its magnesium block.¹⁰ Substance P acting via its receptor, the neurokinin-1 receptor, prolongs this depolarisation and allows further influx of calcium. The increase of calcium in the dorsal horn activates calcium dependent kinases such as protein kinases A and C, which are then able to phosphorylate amino acids within the NMDA receptor to produce a conformational change in the structure. This permanently removes the magnesium block in the receptor and allows it to be activated by glutamate. The process of central sensitisation differs from windup in that the changes remain long after the C-fibre input has ceased. Furthermore, the magnesium is removed by posttranslational changes in the NMDA receptor and is not just depolarisation induced.^{17,22,24}

Central disinhibition

Central disinhibition results from loss of modulatory control mechanisms, which may lead to abnormal excitation of central neurones.²⁵ The main inhibitory neurotransmitter is γ -aminobutyric acid (GABA). It has been shown that suppression of this pathway results in allodynia. Within two weeks after a peripheral nerve injury, GABA receptor levels are reduced. So it seems that down regulation of GABA mediated pathways may be in part responsible for central sensitisation.

Expansion in receptive field size (recruitment)

Receptive fields of dorsal horn neurones contain subliminal areas; these represent a reservoir of activity.²⁶ With ongoing activation after injury there is an expansion of receptive

field size leading to increased perception of pain, resulting in secondary hyperalgesia. This expansion of receptive fields does not reflect peripheral nerve or nerve root distribution, but spinal cord architecture. It might therefore be confusing from a diagnostic point of view, as it transgresses the boundaries imposed by a hard-wired model of the CNS.²⁷

Immediate early gene expression

Immediate changes in gene expression in dorsal horn cells occur in response to A δ - and C-fibre stimulation. These changes persist for a variable length of time and may contribute to central neuroplasticity. Noxious stimulation mediated by A δ - and C-fibres produces an immediate change in the expression of certain genes within the dorsal horn cells.²⁸ These changes are detected within minutes of stimulation and may last for months or even years. The gene *c-fos* encodes for a protein, *fos*, which forms part of a transcription factor which may control the expression of other genes which produce long term changes in the dorsal horn. *C-fos* activation occurs as a result of increases in intracellular calcium following release of neurotransmitters like substance P and glutamate involved in relay of nociceptive information.²⁹ This is followed rapidly by the appearance of *fos* protein which can be detected in laminae I, II and V of the dorsal horn. The presence of *fos* protein can be used as a marker of noxious stimulation and thus also to determine the effect of agents to reduce noxious stimulation.

Anatomical re-organisation of the spinal cord

Primary afferent neurones synapse in the laminae of the dorsal horn with second order ascending neurones. Under normal conditions, A δ - and C-fibres terminate in laminae I and II, whereas A β -fibres terminate in laminae III and IV.

Following C-fibre injury, the large unmyelinated A β -fibres sprout terminals into lamina II. A β -fibres, which are activated by low intensity non-painful stimuli can thus stimulate the dorsal horn neurons present in lamina II, usually associated with noxious sensation.³⁰ This observation could explain allodynia, as A β -fibres form synapses with second order neurones and their low-threshold non-noxious inputs will be signalled as nociceptive in origin.

However, doubt surrounds this theory as a main mechanism of allodynia as sprouting is not fully established until 2 weeks after the injury. Furthermore it has been suggested that this sprouting only occurs in a small subgroup of A β neurones.²¹

As well as sprouting fibres into lamina II, A β -fibres also undergo phenotypic switching and produce the neurotransmitter substance P and calcitonin gene related peptide. These neurotransmitters are usually produced only by C-fibres, but after nerve injury their expression by C-fibres is down-regulated. A β -fibres begin to release these at the dorsal horn following low intensity stimulation. This release of substance P can maintain the central sensitisation changes in the dorsal horn at the NMDA receptor that is usually only maintained by continued C-fibre input.

Contribution of glial cells to pain conditions

There is now increasing recognition that neuropathic pain is not only the result of changes in neuronal cells and pathways, but also that glial cells, thought to be not relevant to neuronal function, play a major role here.³¹ Schwann cells, spinal microglia and astrocytes, more regarded as components of the immune system, seem to have relevant contributions to the development of chronic pain states and make it plausible that these have features of a neuroimmune disorder and may offer new approaches to treatment.

Symptoms of neuropathic pain

Patients with neuropathic pain usually experience persistent and/or paroxysmal pain.¹⁸ The pain often has an abnormal quality, for example burning, electric-shock like, shooting, lancinating or numbing. Neuropathic pain can occur in an area of neurological deficit, but might also arise from areas still innervated normally.³² Neuropathic pain exhibits often one or more of the following characteristic features:

- *Dysaesthesia*, an unpleasant abnormal sensation, whether spontaneous or evoked.
- *Hyperalgesia*, an increased response to a painful stimulus.
- *Allodynia*, pain elicited by a normally non noxious stimulus
- *Hyperpathia*, a painful syndrome characterised by increased reaction to a stimulus, especially a repetitive stimulus, as well as an increased threshold.
- *Hypoalgesia*, diminished pain in response to a normally painful stimulus.

Clinical features of neuropathic pain are often summarised as stimulus-dependent, stimulus-independent and sympathetically-maintained pain:³²

Stimulus-dependent pain

Following nerve injury, increased C-fibre activity causes central sensitisation within the dorsal horn via activation of the NMDA receptor as described earlier.

Central sensitisation produces three main effects:

- 1) enlargement of the sensory field of a dorsal horn neuron (secondary hyperalgesia)
- 2) increase of the response to a supra-threshold stimulus (hyperalgesia)
- 3) generation of a response to a subthreshold stimulus (allodynia)

These phenomena represent stimulus-dependent pain, although the relationship between stimulus and response might be widely varying.

Stimulus independent pain

As mentioned earlier, there are two types of sodium channels present on sensory neurons. The tetrodotoxin resistant channels are implicated in the generation of the spontaneous pain of pathological pain states.

Following injury there is reorganisation of the expression and location of the various types of sodium channel within the neuron. The tetrodotoxin resistant channels relocate to the neuroma, where it produces areas of hyperexcitability and ectopic discharges. After nerve injury, both injured nerves and uninjured nerves close to the site of injury display spontaneous discharges. The alterations in expression of sodium channels are thought to be due to alterations in the supply of neurotrophins such as nerve growth factor and glial-derived neurotrophic factor.³³

Sympathetically maintained pain (SMP)

In a small but significant proportion of chronic pain sufferers the pain has a definite sympathetic system element to it and is said to be sympathetically maintained.

Following partial nerve injury in these patients, both injured and uninjured primary afferents express alpha-2 adrenoceptors on their membranes so they become sensitive to circulating catecholamines and noradrenaline release from sympathetic nerve terminals.¹⁷

Direct coupling also occurs between the sympathetic and peripheral nervous systems with sympathetic nerves sprouting axons into the dorsal root ganglion to form baskets around the cell bodies of nociceptor neurons, where they form functional synapses. This sprouting is thought to occur under the

influence of nerve growth factor. Other more central mechanisms of somatosensory-sympathetic coupling are also investigated.²³

Neuropathic pain syndromes

There are many causes of neuropathic pain including a number of disease states.

Peripheral neuropathies

Metabolic/Endocrine: Diabetics can develop different types of neuropathies, these include polyneuropathies, autonomic neuropathy, compression neuropathy and focal neuropathies. There are more than 15 million diabetics in the USA and more than half of them over 60 years have neuropathic pain.

Many diabetics, especially those with poor blood glucose control develop a distal, symmetrical, proximally spreading and painful neuropathy.³⁴ Severe pain is often a feature and may be described as burning, aching or have lightning components to it. It seems that the main cause is demyelination and to a lesser extent axonal degeneration. The first stage in prevention and treatment of early neuropathies is good glycaemic control. Additionally, hyperglycaemia may have a direct effect on neuropathic pain by altering pain thresholds, tolerance and affecting opioid receptors.

Mononeuropathies, usually involve the motor supply to extraocular muscles and also nerve supply to the limbs. The third cranial nerve is most frequently affected. Pain is often a symptom. Additionally, an asymmetrical proximal predominantly motor neuropathy can occur, especially in older patients with poor glycaemic control.

Untreated hypothyroidism may result in neuropathic pain.

Toxic: Well-known neuropathies here include those caused by alcohol, chemotherapy (where the neuropathy maybe the dose

limiting factor) and, more recently anti-AIDS drugs e.g. isoniazid.

Postinfectious: The most common problem here is Post Herpetic Neuropathy (PHN), which increases in incidence, intensity and persistence with age.³⁵ The pain persists in the distribution of a peripheral nerve after herpes zoster infection (shingles). It is thought that chronic inflammatory changes result in damage to sensory nerves resulting in deafferentation of nociceptive fibres. The pain is persistent and can become intolerable with associated allodynia. Treatment is very difficult, particularly in later stages.

Hereditary: Fabry's disease, a rare lipid storage disorder, often presents with a painful neuropathy.

Malignant: Neuropathies can occur as a non-metastatic complication of malignant disease, usually a sensory neuropathy that can sometimes be painful. Neuropathic pain can also be caused as the result of direct tumour invasion involving nearby nerves.

Idiopathic: Trigeminal neuralgia (tic douloureux) is defined by the IASP as a 'sudden, usually unilateral, severe, brief, stabbing, recurrent pains in the distribution of one or more branches of the fifth cranial nerve'.¹ It can occasionally be secondary to an underlying condition e.g. tumour, multiple sclerosis. The diagnosis is made on clinical grounds as the patients describe a characteristic pain. It occurs most frequently in the maxillary division and least in the ophthalmic division of the trigeminal nerve. The pain is triggered by light touch, eating, talking and the cold. Examination in the absence of other neurological symptoms reveals very little. There is no definitive diagnostic test. Magnetic resonance imaging (MRI) can reveal an underlying cause or nerve compression, but is otherwise not highly sensitive or specific. Magnetic resonance

tomographic angiography (MRTA) has been used in delineating the pathophysiological process and may provide a helpful diagnostic image but there is insufficient evidence at present.

The pathophysiology is not completely understood. The most evidence supports vascular compression of the nerve, resulting in hyperexcitability and abnormal neuronal activity, causing pain. This theory is supported by the fact that patients often experience immediate pain relief from microvascular decompression and has been confirmed radiologically in a study utilising MRTA.³⁶

Spontaneous remission may occur so surgery is reserved for those refractory to medical treatment. Complications of surgical microvascular decompression include facial nerve damage, haematoma, cerebrospinal fluid leak and infection. However, despite its risks microvascular decompression is currently the best option from a variety of surgical procedures. The other surgical techniques include gasserian ganglion surgery, radiofrequency thermocoagulation, percutaneous retro Gasserian glycerol injection or microcompression, posterior fossa surgery and gamma knife irradiation.

Patients should be made aware of the risks associated with the chosen surgical technique and warned that the pain relief may not be permanent and balance these against the benefit from potential long term analgesia in cases refractory to medical management.³⁷

Vascular: Vascular pain is a complex issue. Pain can be arterial, microvascular or venous in origin. Neuropathy can in particular follow venous insufficiency.³⁸ In every vascular disease, sympathetic changes may develop which contribute a neuropathic element to the ischaemic pain. The patient may develop skin hyperalgesia, dystrophic skin with a shiny appearance, muscle atrophy and vasomotor

phenomena. Sympathetic blocks may be beneficial.³⁹

Posttraumatic: Posttraumatic neuropathies are common and can develop after any nerve injury. Even minor demyelination injuries without neurological sequelae can result in neuropathies. Examples are sciatica, neuroma or nerve entrapment after surgery or trauma, phantom limb pain, complex regional pain syndromes (CRPS) type I (without neurological deficit, previously called Reflex Sympathetic Dystrophy RSD) and Type II (with neurological deficit, previously called causalgia) and post-thoracotomy pain.

Central neuropathies

Central pain is due to a lesion or dysfunction of the CNS.⁴⁰ These lesions may have associated symptoms that affect the patient and their pain eg ataxia, motor weakness and hearing/visual loss. Epilepsy and depression are also common with cerebral lesions. These aspects need to be addressed along with treatment of the pain.

Central pain is associated with spinothalamocortical dysfunction and may develop over a length of time and varies widely between individuals regardless of aetiology.

Vascular lesions in the brain and spinal cord:

The aetiology here includes infarction, haemorrhage, and vascular malformation. Stroke is the most common cause of central pain due to its high incidence.⁴¹ Around 8% of patients with acute stroke have been shown to suffer from central pain in the following 12 months.

Multiple sclerosis: This demyelination process can result in neuropathic pain by a variety of mechanisms. Cranial nerve neuropathies, but also widespread central pain syndromes are common consequences and often difficult to treat.⁴²


Trauma, tumours and infections: Brain injury, but by far more commonly spinal cord injury, can result in a variety of central pain syndromes.⁴³ Syringomyelia and syringobulbia as a consequence of such injuries can cause further central pain. Tumours of the brain and spine as well as infections and abscesses can cause similar symptoms.⁴⁰

REFERENCES

- 1 Merskey H, Bogduk N, editors. *Classification of Chronic Pain*. 2nd ed. Seattle: IASP Press; 1994.
- 2 Woolf C. Somatic pain – pathogenesis and prevention. *British Journal of Anaesthesia* 1995; **75**: 169–176.
- 3 Siddall PJ, Cousins MJ. Persistent pain as a disease entity: implications for clinical management. *Anesth Analg* 2004; **99**: 510–20.
- 4 Costigan M, Scholz J, Woolf CJ. Neuropathic pain: a maladaptive response of the nervous system to damage. *Annu Rev Neurosci* 2009; **32**: 1–32.
- 5 Broad LM, Mogg AJ, Beattie RE, et al. TRP channels as emerging targets for pain therapeutics. *Expert Opin Ther Targets* 2009; **13**: 69–81.
- 6 Cattaneo A. Tanazumab, a recombinant humanized mAb against nerve growth factor for the treatment of acute and chronic pain. *Curr Opin Mol Ther* 2010; **12**: 94–106.
- 7 Priest BT. Future potential and status of selective sodium channel blockers for the treatment of pain. *Curr Opin Drug Discov Devel* 2009; **12**: 682–92.
- 8 Taylor CP. Mechanisms of analgesia by gabapentin and pregabalin – calcium channel alpha2-delta [Cavalpha2-delta] ligands. *Pain* 2009; **142**: 13–6.

- 9 Bolay H, Moskowitz MA. Mechanisms of pain modulation in chronic syndromes. *Neurology* 2002; **59**: S2–7.
- 10 Eide PK. Wind-up and the NMDA receptor complex from a clinical perspective. *Eur J Pain* 2000; **4**: 5–17.
- 11 Millan MJ. The induction of pain: an integrative review. *Prog Neurobiol* 1999; **57**: 1–164.
- 12 Stamford JA. Descending control of pain. *Br J Anaesth* 1995; **75**: 217–27.
- 13 D'Mello R, Dickenson AH. Spinal cord mechanisms of pain. *Br J Anaesth* 2008; **101**: 8–16.
- 14 Melzack R, Wall PD. Pain mechanisms: A new theory. *Science* 1965; **150**: 971–79.
- 15 Kidd BL, Urban LA. Mechanisms of inflammatory pain. *Br J Anaesth* 2001; **87**: 3–11.
- 16 Dickenson AH. Gate control theory of pain stands the test of time. *Br J Anaesth* 2002; **88**: 755–7.
- 17 Mannion RJ, Woolf CJ. Pain mechanisms and management: a central perspective. *Clin J Pain* 2000; **16**: S144–56.
- 18 Woolf CJ, Mannion RJ. Neuropathic pain: aetiology, symptoms, mechanisms, and management. *Lancet* 1999; **353**: 1959–64.
- 19 Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. *Lancet Neurol* 2010; **9**: 807–19.
- 20 Devor M, Seltzer Z. Pathophysiology of damaged nerves in relation to chronic pain. In: Wall PD, Melzack R, editors. *Textbook of Pain*. 4th ed. London: Churchill Livingstone; 1999; 129–164.
- 21 McMahon SB, Bennett DLH. Trophic factors and pain. In: Wall PD, Melzack R, editors. *Textbook of Pain*.
- 22 Woolf CJ, Salter MW. Neuronal plasticity: increasing the gain in pain. *Science* 2000; **288**: 1765–9.
- 23 Janig W, Habler HJ. Sympathetic nervous system: contribution to chronic pain. *Prog Brain Res* 2000; **129**: 451–68.
- 24 Woolf CJ, Costigan M. Transcriptional and posttranslational plasticity and the generation of inflammatory pain. *Proc Nat Acad Sci USA* 1999; **96**: 7723–30.
- 25 Attal N. Chronic neuropathic pain: mechanisms and treatment. *Clin J Pain* 2000; **16**: S118–30.
- 26 Wall PD. Recruitment of ineffective synapses after injury. *Adv Neurol* 1988; **47**: 387–400.
- 27 Coghill RC, Mayer DJ, Price DD. The roles of spatial recruitment and discharge frequency in spinal cord coding of pain: a combined electrophysiological and imaging investigation. *Pain* 1993; **53**: 295–309.
- 28 Munglani R, Hunt SP. Molecular biology of pain. *Br J Anaesth* 1995; **75**: 186–92.
- 29 Munglani R, Fleming BG, Hunt SP. Rememberance of times past: the significance of c-fos in pain (Editorial). *Br J Anaesth* 1996; **76**: 1–3.
- 30 Woolf CJ, Shortland P, Reynolds M, et al. Reorganization of central terminals of myelinated primary afferents in the rat dorsal horn following peripheral axotomy. *J Comp Neurol* 1995; **360**: 121–34.
- 31 Scholz J, Woolf CJ. The neuropathic pain triad: neurons, immune cells and glia. *Nat Neurosci* 2007; **10**: 1361–8.
- 32 Baron R, Tolle TR. Assessment and diagnosis of neuropathic pain. *Curr Opin Support Palliat Care* 2008; **2**: 1–8.

- 33 Waxman SG, Cummins TR, Dib-Hajj SD, Black JA. Voltage-gated sodium channels and the molecular pathogenesis of pain: a review. *J Rehabil Res Dev* 2000; **37**: 517–28.
- 34 Chong MS, Hester J. Diabetic painful neuropathy: current and future treatment options. *Drugs* 2007; **67**: 569–85.
- 35 Johnson RW. Zoster-associated pain: what is known, who is at risk and how can it be managed? *Herpes* 2007; **14** Suppl 2: 30–4.
- 36 Zakrzewska JM. Trigeminal neuralgia. *Clin Evid* 2003: 1490–8.
- 37 Zakrzewska JM. Medical management of trigeminal neuropathic pains. *Expert Opin Pharmacother* 2010; **11**: 1239–54.
- 38 Reinhardt F, Wetzel T, Vettén S, et al. Peripheral neuropathy in chronic venous insufficiency. *Muscle Nerve* 2000; **23**: 883–7.
- 39 Mailis A, Furlan A. Sympathectomy for neuropathic pain (Cochrane Review). *Cochrane Database Syst Rev* 2003: CD002918.
- 40 Finnerup NB. A review of central neuropathic pain states. *Curr Opin Anaesthesiol* 2008; **21**: 586–9.
- 41 Kim JS. Post-stroke pain. *Expert Rev Neurother* 2009; **9**: 711–21.
- 42 Osterberg A, Boivie J, Thuomas KA. Central pain in multiple sclerosis – prevalence and clinical characteristics. *Eur J Pain* 2005; **9**: 531–42.
- 43 Siddall PJ, McClelland JM, Rutkowski SB, Cousins MJ. A longitudinal study of the prevalence and characteristics of pain in the first 5 years following spinal cord injury. *Pain* 2003; **103**: 249–57.



Cover diagram by David Heinrich of
the *Medical Illustration and Media Unit,*
Flinders Medical Centre. (See chapter 18)

MECHANISMS OF VASCULAR DISEASE

Edited by Robert Fitridge and Matthew Thompson

- Chapter 1:** Endothelium **Chapter 2:** Vascular smooth muscle structure and function **Chapter 3:** Atherosclerosis **Chapter 4:** Mechanisms of plaque rupture **Chapter 5:** Current and emerging therapies in atheroprotection **Chapter 6:** Molecular approaches to revascularisation in peripheral vascular disease **Chapter 7:** Biology of restenosis and targets for intervention **Chapter 8:** Vascular arterial haemodynamics **Chapter 9:** Physiological haemostasis **Chapter 10:** Hypercoagulable states **Chapter 11:** Platelets in the pathogenesis of vascular disease and their role as a therapeutic target **Chapter 12:** Pathogenesis of aortic aneurysms **Chapter 13:** Pharmacological treatment of aneurysms **Chapter 14:** Aortic dissection and connective tissue disorders **Chapter 15:** Biomarkers in vascular disease **Chapter 16:** Pathophysiology and principles of management of vasculitis and Raynaud's phenomenon **Chapter 17:** SIRS, sepsis and multiorgan failure **Chapter 18:** Pathophysiology of reperfusion injury **Chapter 19:** Compartment syndrome **Chapter 20:** Pathophysiology of pain **Chapter 21:** Postamputation pain **Chapter 22:** Treatment of neuropathic pain **Chapter 23:** Principles of wound healing **Chapter 24:** Pathophysiology and principles of varicose veins **Chapter 25:** Chronic venous insufficiency and leg ulceration: Principles and vascular biology **Chapter 26:** Pathophysiology and principles of management of the diabetic foot **Chapter 27:** Lymphoedema – Principles, genetics and pathophysiology **Chapter 28:** Graft materials past and future **Chapter 29:** Pathophysiology of vascular graft infections



BARR SMITH PRESS

An imprint of
The University of Adelaide Press